Aptose Corporate Presentation April 2023
Aptose Clinical Update
For Fiscal Year Ending Dec 31, 2022
Stay informed and receive company updates straight to your inbox.
Aptose Biosciences is a clinical-stage biotechnology company developing differentiated therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research. The company's pipeline includes small molecules designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
Aptose Biosciences Inc.
12770 High Bluff Drive Suite 120 San Diego, CA 92130 USA
Computershare Investor Services www.Computershare.com